Founded in 1966, Lotus is a leading generic company headquartered in Taiwan with comprehensive product portfolio covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsules. Lotus is actively expanding its businesses in export markets such as US, Japan & China, focusing on high value, difficult-to-make generics. Lotus runs the only plant in Taiwan approved by US FDA, EU EMA, & JP PMDA. In 2014, the fast growing international pharmaceutical Alvogen invested in Lotus via private placement and has thus become its majority shareholder. With Alvogen’s global RD, sales & marketing resources, Lotus is now well positioned to become top 5 in APAC region.